{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:07:12Z","timestamp":1794017232837,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004473","name":"Sakarya \u00dcniversitesi","doi-asserted-by":"publisher","award":["2022-9-33-47"],"award-info":[{"award-number":["2022-9-33-47"]}],"id":[{"id":"10.13039\/501100004473","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03844-x","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:52:42Z","timestamp":1762249962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dual inhibition of ATR and PARP reverses acquired PARP inhibitor resistance in triple negative breast cancer"],"prefix":"10.1007","volume":"16","author":[{"given":"Gamze","family":"Guney Eskiler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayten","family":"Haciefendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cemil","family":"Bilir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"5","key":"3844_CR1","doi-asserted-by":"publisher","first-page":"e841","DOI":"10.1016\/j.clbc.2018.07.023","volume":"18","author":"Z Sporikova","year":"2018","unstructured":"Sporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic markers in triple-negative breast cancer. Clin Breast Cancer. 2018;18(5):e841\u201350.","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"3844_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/path.4280","volume":"232","author":"BD Lehmann","year":"2014","unstructured":"Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232(2):142\u201350.","journal-title":"J Pathol"},{"key":"3844_CR3","doi-asserted-by":"crossref","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","DOI":"10.3322\/caac.21820"},{"issue":"9","key":"3844_CR4","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1634\/theoncologist.2016-0067","volume":"21","author":"P Sharma","year":"2016","unstructured":"Sharma P. Biology and management of patients with triple-negative breast cancer. Oncologist. 2016;21(9):1050\u201362.","journal-title":"Oncologist"},{"issue":"3","key":"3844_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.32604\/or.2023.028525","volume":"31","author":"LS Popovic","year":"2023","unstructured":"Popovic LS, Matovina-Brko G, Popovic M, Punie K, Lambertini CA. Targeting triple-negative breast cancer: A clinical perspective. Oncol Res. 2023;31(3):221.","journal-title":"Oncol Res"},{"key":"3844_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","volume":"286\u2013287","author":"D Sonkin","year":"2024","unstructured":"Sonkin D, Thomas A, Teicher BA. Cancer treatments: Past, present, and future. Cancer Genet. 2024;286\u2013287:18\u201324.","journal-title":"Cancer Genet"},{"issue":"1","key":"3844_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, Wu K. Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol. 2023;16(1):100.","journal-title":"J Hematol Oncol"},{"key":"3844_CR8","doi-asserted-by":"publisher","first-page":"731535","DOI":"10.3389\/fonc.2021.731535","volume":"11","author":"Y Li","year":"2021","unstructured":"Li Y, Zhan Z, Yin X, Fu S, Deng X. Targeted therapeutic strategies for triple-negative breast cancer. Front Oncol. 2021;11:731535.","journal-title":"Front Oncol"},{"issue":"11","key":"3844_CR9","first-page":"1512","volume":"9","author":"DD Singh","year":"2021","unstructured":"Singh DD, Parveen A, Yadav DK. Role of PARP in TNBC: mechanism of inhibition, clinical applications, and resistance. Biomed. 2021;9(11):1512.","journal-title":"Biomed"},{"issue":"5","key":"3844_CR10","doi-asserted-by":"publisher","first-page":"e22286","DOI":"10.1002\/jbt.22286","volume":"33","author":"G Guney Eskiler","year":"2019","unstructured":"Guney Eskiler G, Cecener G, Egeli U, Tunca B. BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019;33(5):e22286.","journal-title":"J Biochem Mol Toxicol"},{"issue":"12","key":"3844_CR11","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Reviews Clin Oncol. 2021;18(12):773\u201391.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"9","key":"3844_CR12","doi-asserted-by":"publisher","first-page":"6230","DOI":"10.1002\/jcp.29552","volume":"235","author":"G Guney Eskiler","year":"2020","unstructured":"Guney Eskiler G, Cecener G, Egeli U, Tunca B. Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer. J Cell Physiol. 2020;235(9):6230\u201345.","journal-title":"J Cell Physiol"},{"issue":"12","key":"3844_CR13","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.trecan.2021.08.007","volume":"7","author":"K Fugger","year":"2021","unstructured":"Fugger K, Hewitt G, West SC, Boulton SJ. Tackling PARP inhibitor resistance. Trends Cancer. 2021;7(12):1102\u201318.","journal-title":"Trends Cancer"},{"key":"3844_CR14","doi-asserted-by":"publisher","first-page":"578095","DOI":"10.3389\/fonc.2020.578095","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Yu X, Li S, Tian Y, Liu C. New perspectives for resistance to PARP inhibitors in triple-negative breast cancer. Front Oncol. 2020;10:578095.","journal-title":"Front Oncol"},{"key":"3844_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-1085-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: the underlying mechanisms and clini-cal implications. Mol Cancer. 2020;19:1\u201316.","journal-title":"Mol Cancer"},{"key":"3844_CR16","doi-asserted-by":"publisher","first-page":"103099","DOI":"10.1016\/j.dnarep.2021.103099","volume":"101","author":"T Brooks","year":"2021","unstructured":"Brooks T, Wayne J, Massey AJ. Chk1 Inhibition induces a DNA damage bystander effect in cocultured tumour cells. DNA Rep. 2021;101:103099.","journal-title":"DNA Rep"},{"issue":"11","key":"3844_CR17","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1158\/1535-7163.MCT-18-0470","volume":"17","author":"X Tu","year":"2018","unstructured":"Tu X, Kahila MM, Zhou Q, Yu J, Kalari KR, Wang L, Harmsen WS, Yuan J, Boughey JC, Goetz MP, Sarkaria JN, Lou Z, Mutter RW. ATR Inhibition is a promising radiosensitizing strategy for triple-negative breast cancer. Mol Cancer Ther. 2018;17(11):2462\u201372.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"3844_CR18","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.neo.2018.03.003","volume":"20","author":"J Jin","year":"2018","unstructured":"Jin J, Fang H, Yang F, Ji W, Guan N, Sun Z, Shi Y, Zhou G, Guan X. Combined Inhibition of ATR and WEE1 as a novel therapeutic strategy in triple-negative breast cancer. Neoplasia. 2018;20(5):478\u201388.","journal-title":"Neoplasia"},{"key":"3844_CR19","first-page":"541","volume":"39","author":"N Turner","year":"2013","unstructured":"Turner N, Moretti E, Siclari O, Migliaccio I, Santarpia L, D\u2019Incalci M, Piccolo S, Veronesi A, Zambelli A, Del Sal G, et al. Targeting triple negative breast cancer: is P53 the answer? Cancer treat. Rev. 2013;39:541\u201350.","journal-title":"Rev"},{"issue":"1","key":"3844_CR20","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, Medvedev S, Kinose Y, Devins K, Verma P, Ly K, Wang Y, Greenberg RA, Schwartz L, Johnson N, Scharpf RB, Mills GB, Zhang R, Velculescu VE, Brown EJ, Simpkins F. Combining PARP with ATR Inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun. 2020;11(1):3726.","journal-title":"Nat Commun"},{"issue":"2021","key":"3844_CR21","first-page":"100017","volume":"2","author":"FM Barnieh","year":"2021","unstructured":"Barnieh FM, Loadman PM, Falconer RA. Progress towards a clinically-successful ATR inhibitor for cancer therapy. CRPHAR. 2021;2(2021):100017.","journal-title":"CRPHAR"},{"issue":"1","key":"3844_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","volume":"19","author":"AM Wengner","year":"2020","unstructured":"Wengner AM, Siemeister G, L\u00fccking U, Lefranc J, Wortmann L, Lienau P, Bader B, et al. The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage\u2013inducing or repair\u2013compromising therapies in preclinical cancer models antitumor effects of ATR Inhibition. Mol Cancer Ther. 2020;19(1):26\u201338.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"3844_CR23","first-page":"4902","volume":"15","author":"A Haciefendi","year":"2023","unstructured":"Haciefendi A, Guney Eskiler G. The suppression of ATR\/Chk1 pathway by elimusertib ATR inhibitor in triple negative breast cancer cells. Am J Transl Res. 2023;15(7):4902.","journal-title":"Am J Transl Res"},{"key":"3844_CR24","doi-asserted-by":"crossref","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, Pessia A, Tang J. SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets. GBP 2022;20:587\u2013596.","DOI":"10.1016\/j.gpb.2022.01.004"},{"issue":"3","key":"3844_CR25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621\u201381.","journal-title":"Pharmacol Rev"},{"key":"3844_CR26","doi-asserted-by":"publisher","first-page":"7139","DOI":"10.1158\/0008-5472.CAN-04-1289","volume":"64","author":"H Wang","year":"2004","unstructured":"Wang H, Wang H, Powell SN, Iliakis G, Wang Y. ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining. Cancer Res. 2004;64:7139\u201343.","journal-title":"Cancer Res"},{"key":"3844_CR27","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm2450","volume":"9","author":"KA Cimprich","year":"2008","unstructured":"Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008;9:616\u201327.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3844_CR28","first-page":"100017","volume":"2","author":"FM Barnieh","year":"2021","unstructured":"Barnieh FM, Loadman PM, Falconer RA. Progress towards a clinically-successful ATR inhibitor for cancer therapy. CRPHAR. 2021;2:100017.","journal-title":"CRPHAR"},{"issue":"3","key":"3844_CR29","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1101\/gad.290957.116","volume":"31","author":"SA Yazinski","year":"2017","unstructured":"Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, et al. ATR Inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 2017;31(3):318\u201332.","journal-title":"Genes Dev"},{"key":"3844_CR30","first-page":"1","volume-title":"Interdisciplinary cancer Research; Nima Rezaei","author":"A Haciefendi","year":"2024","unstructured":"Haciefendi A, Guney Eskiler G. Therapeutic targeting of ATR in cancer. Interdisciplinary cancer Research; Nima Rezaei. Cham: Springer; 2024. pp. 1\u201320."},{"issue":"47","key":"3844_CR31","doi-asserted-by":"publisher","first-page":"39246","DOI":"10.1074\/jbc.M505009200","volume":"280","author":"H Niida","year":"2005","unstructured":"Niida H, Tsuge S, Katsuno Y, Konishi A, Takeda N. Nakanishi. Depletion of Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe. J Biol Chem. 2005;280(47):39246\u201352.","journal-title":"J Biol Chem"},{"issue":"1","key":"3844_CR32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, et al. First-in-Human trial of the oral ataxia telangiectasia and RAD3-Related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov. 2021;11(1):80\u201391.","journal-title":"Cancer Discov"},{"key":"3844_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ygyno.2024.10.009","volume":"191","author":"SP Elayapillai","year":"2024","unstructured":"Elayapillai SP, Dogra S, Lausen J, Parker M, Kennedy A, Benbrook DM, Moxley KM, Hannafon BN. ATR Inhibition increases reliance on PARP-mediated DNA repair revealing an improved therapeutic strategy for cervical cancer. Gynecol Oncol. 2024;191:182\u201393.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"3844_CR34","doi-asserted-by":"publisher","first-page":"111081","DOI":"10.1016\/j.celrep.2022.111081","volume":"40","author":"M Zimmermann","year":"2022","unstructured":"Zimmermann M, Bernier C, Kaiser B, Fournier S, Li L, Desjardins J, Skeldon A, Rimkunas V, Veloso A, Young JTF, Roulston A, Zinda M. Guiding ATR and PARP inhibitor combinations with chemogenomic screens. Cell Rep. 2022;40(2):111081.","journal-title":"Cell Rep"},{"issue":"5","key":"3844_CR35","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41416-024-02745-0","volume":"131","author":"HL Smith","year":"2024","unstructured":"Smith HL, Willmore E, Prendergast L, Curtin NJ. ATR, CHK1 and WEE1 inhibitors cause homologous recombina-tion repair deficiency to induce synthetic lethality with PARP inhibitors. Br J Cancer. 2024;131(5):905\u201317.","journal-title":"Br J Cancer"},{"issue":"15","key":"3844_CR36","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","volume":"29","author":"SL Wethington","year":"2023","unstructured":"Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA, Rodriguez D, et al. Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-Resistant Ho-mologous Recombination-Deficient ovarian cancer. Clin Cancer Res. 2023;29(15):2800\u20137.","journal-title":"Clin Cancer Res"},{"key":"3844_CR37","doi-asserted-by":"crossref","unstructured":"Guney Eskiler G, Yanar S, Akpinar G, Kasap M. Proteomic analysis of Talazoparib resistance in triple-negative breast cancer cells. J Biochem Mol Toxicol. 2021;35(3):e22678.","DOI":"10.1002\/jbt.22678"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03844-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03844-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03844-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T21:04:10Z","timestamp":1762290250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03844-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3844"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03844-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2020"}}